2014
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International 2014, 14: 4. PMID: 24423208, PMCID: PMC3896780, DOI: 10.1186/1475-2867-14-4.Peer-Reviewed Original ResearchRenal cell carcinomaMicrovessel areaHighest microvessel areaSorafenib responseCell carcinomaMetastatic renal cell carcinomaCD 34 stainingSmall primary tumorsProgression-free survivalAnti-angiogenic therapyVEGF-R2 inhibitorsAdditional patientsPatient selectionPredictive biomarkersPrimary tumorSorafenib sensitivityTumor specimensDrug AdministrationVEGF-R3VEGF-R1Immunofluorescence-based methodTumor samplesVEGF-R2C-kitPatients
2007
Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome
Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.Peer-Reviewed Original ResearchConceptsCOX-2 expressionCOX-2Tissue microarrayBreast cancerEstrogen receptorPrognostic factorsWorse survivalProgesterone receptorX-tileOptimal cutpointHigh COX-2 expressionBreast cancer tissue microarrayX-tile analysisSignificant prognostic factorsPrimary breast cancerCOX-2 inhibitorsCancer tissue microarrayHER2/neuClinicopathologic factorsNodal statusPoor outcomePoor prognosisTumor sizePredictive biomarkersClinical trials